AAAAAA
Results:
1-12
|
Results: 12
Authors:
Vuoristo, MS
Laine, S
Huhtala, H
Parvinen, LM
Hahka-Kemppinen, M
Korpela, M
Kumpulainen, E
Kellokumpu-Lehtinen, P
Citation: Ms. Vuoristo et al., Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma, EUR J CANC, 37(13), 2001, pp. 1629-1634
Authors:
Hinkka, H
Kosunen, E
Kellokumpu-Lehtinen, P
Lammi, UK
Citation: H. Hinkka et al., Assessment of pain control in cancer patients during the last week of life: comparison of health centre wards and a hospice, SUPP CARE C, 9(6), 2001, pp. 428-434
Authors:
Lammi, UK
Kosunen, E
Kellokumpu-Lehtinen, P
Citation: Uk. Lammi et al., Palliative cancer care in two health centres and one hospice in Finland, SUPP CARE C, 9(1), 2001, pp. 25-31
Authors:
Hinkka, H
Kosunen, E
Metsanoja, R
Lammi, UK
Kellokumpu-Lehtinen, P
Citation: H. Hinkka et al., To resuscitate or not: a dilemma in terminal cancer care, RESUSCITAT, 49(3), 2001, pp. 289-297
Authors:
Choi, N
Baumann, M
Flentjie, M
Kellokumpu-Lehtinen, P
Senan, S
Zamboglou, N
Kosmidis, P
Citation: N. Choi et al., Predictive factors in radiotherapy for non-small cell lung cancer: presentstatus, LUNG CANC, 31(1), 2001, pp. 43-56
Authors:
Vuoristo, MS
Kellokumpu-Lehtinen, P
Laine, S
Parvinen, LM
Hahka-Kemppinen, M
Korpela, M
Kumpulainen, E
Citation: Ms. Vuoristo et al., The value of serum S-100 beta and interleukins as tumour markers in advanced melanoma, MELANOMA RE, 10(3), 2000, pp. 237-241
Authors:
Vuoristo, MS
Kellokumpu-Lehtinen, P
Parvinen, LM
Hahka-Kemppinen, M
Korpela, M
Kumpulainen, E
Laine, S
Citation: Ms. Vuoristo et al., Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma, ACTA ONCOL, 39(7), 2000, pp. 877-879
Authors:
Bergh, J
Wiklund, T
Erikstein, B
Lidbrink, E
Lindman, H
Malmstrom, P
Kellokumpu-Lehtinen, P
Bengtsson, NO
Soderlund, G
Anker, G
Wist, E
Ottosson, S
Salminen, E
Ljungman, P
Holte, H
Nilsson, J
Blomqvist, C
Wilking, N
Citation: J. Bergh et al., Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial, LANCET, 356(9239), 2000, pp. 1384-1391
Authors:
Honkaniemi, J
Kahara, V
Dastidar, P
Latvala, M
Hietaharju, A
Salonen, T
Keskinen, L
Ollikainen, J
Vahamaki, L
Kellokumpu-Lehtinen, P
Frey, H
Citation: J. Honkaniemi et al., Reversible posterior leukoencephalopathy after combination chemotherapy, NEURORADIOL, 42(12), 2000, pp. 895-899
Authors:
Oivanen, T
Kellokumpu-Lehtinen, P
Koivisto, AM
Koivunen, E
Citation: T. Oivanen et al., Response rate and survival after conventional chemotherapy for multiple myeloma by hospitals with different inclusion rates of patients to the trials. A Finnish Leukemia Group study, EUR J HAEMA, 63(4), 1999, pp. 225-230
Authors:
Oivanen, TM
Kellokumpu-Lehtinen, P
Koivisto, AM
Koivunen, E
Palva, I
Citation: Tm. Oivanen et al., Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study, EUR J HAEMA, 62(2), 1999, pp. 109-116
DNA sequence copy number increase at 8q: A potential new prognostic markerin high-grade osteosarcoma
Authors:
Tarkkanen, M
Elomaa, I
Blomqvist, C
Kivioja, AH
Kellokumpu-Lehtinen, P
Bohling, T
Valle, J
Knuutila, S
Citation: M. Tarkkanen et al., DNA sequence copy number increase at 8q: A potential new prognostic markerin high-grade osteosarcoma, INT J CANC, 84(2), 1999, pp. 114-121
Risultati:
1-12
|